Cizutamig treatment for active thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new drug called cizutamig for thyroid eye disease (TED), a condition where the eye muscles and tissues swell due to Graves' disease. The drug is designed to reduce inflammation and may help improve symptoms like eye bulging, double vision, and discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with Graves' disease and moderate-to-severe active thyroid eye disease
- No active infections or tuberculosis (or completed TB treatment with documentation)
- No history of serious immune system disorders or certain brain/nervous system conditions
- No cancer diagnosis in the past 5 years
- Able to stop excluded medications before and during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This study tests a new medication called MHB018A for people with chronic Thyroid Eye Disease (TED) that is moderate to severe. It aims to see if the drug can help improve symptoms and quality of life over time.
This trial tests a new drug called ZL-1109 for people with active, moderate to severe thyroid eye disease (TED). It aims to see if the drug can reduce symptoms like bulging eyes and help patients feel better without using steroids.
This study tests whether a new medicine called MHB018A can reduce swelling and inflammation in thyroid eye disease (TED)—a condition where the immune system attacks tissues around the eyes, causing them to swell, bulge, and become uncomfortable. Researchers will compare MHB018A to placebo (a fake medicine) to see if it helps improve symptoms and appearance.
This trial tests a new drug called MHB018A for chronic thyroid eye disease (TED)—a condition where the eyes become inflamed and swollen due to thyroid problems. The study aims to see if this treatment can reduce eye inflammation and improve symptoms in people who have had TED for over a year.
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.